시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 원발성 진행성 다발성 경화증(PPMS) 치료 시장 보고서(2025년)
Primary Progressive Multiple Sclerosis (PPMS) Treatment Global Market Report 2025
상품코드 : 1769721
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,471,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,354,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,236,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

원발성 진행성 다발성 경화증(PPMS) 치료 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 예상되는 성장의 원동력은 신규 PPMS 치료법을 모색하는 임상시험 증가, 진단법의 진보, 정밀의료나 표적의료에 대한 기호의 향상, 헬스케어 인프라의 개선, 제약기업간의 제휴와 파트너십의 강화 등입니다. 예측 기간 중에 예상되는 주요 동향으로서는 PPMS의 진행 저지를 목적으로 한 질환 수식 요법의 혁신, 맞춤형 치료를 위한 바이오마커 연구의 응용, MRI 등의 화상 기술의 강화, 신경 보호·재수초화약의 개발에 있어서의 진보, 보다 정확한 치료 계획을 위한 유전자 및 분자 환자 프로파일링의 획기적인 발전이 있습니다.

효과적인 치료에 대한 수요가 높아지면서 향후 원발성 진행성 다발성 경화증(PPMS) 치료 시장의 성장을 가속할 것으로 예측됩니다. 이러한 수요는 주로 만성적이고 복잡한 건강 상태의 유병률이 증가함에 따라 발생하며, 환자의 결과와 삶의 질을 개선하기 위해 장기적인 관리와 고급 치료 개입이 필요합니다. 이러한 치료법은 염증을 표적으로 삼고 신경 기능을 보존함으로써 원발성 진행성 다발성 경화증(PPMS)의 진행을 늦추는 데 도움이 되며, 이를 통해 장기적인 삶의 질을 개선하고 장애 축적을 줄이며, 환자들이 더 큰 독립성과 안정성을 가지고 일상 활동을 관리할 수 있는 능력을 향상시킵니다. 2024년 1월, 미국 유전자 및 세포 치료 학회(American Society of Gene & Cell Therapy)에 따르면, 2023년 유전자 치료제 임상 3상 시험 건수는 33건에 달하여 2022년 대비 10% 증가했으며, 이는 2022년 3분기 이후 첫 분기별 증가를 나타냈습니다.

원발성 진행성 다발성 경화증(PPMS) 치료 시장에서 사업을 전개하는 주요 기업은 다발성 경화증의 치료를 강화하기 위해 단일클론항체 의약과 같은 혁신적인 제형의 개발에 주력하고 있습니다. 단일클론항체 의약품은 염증이나 신경계에 손상을 일으키는 특정 면역세포와 단백질을 표적으로 함으로써 다발성 경화증의 치료에 도움이 되고, 질환 활동성을 저하시키고, 증상의 진행을 지연시킵니다. 예를 들어, 2024년 2월, 인도 제약 회사인 Roche Pharma India는 인도에서 다발성 경화증(MS)의 치료제로 단일클론 항체 약물 Ocrevus (ocrelizumab)를 출시했습니다. Ocrevus는 재발 완화형 다발성 경화증(RRMS)과 원발성 진행성 다발성 경화증(PPMS) 모두에 대해 인도에서 처음으로 유일하게 승인된 질병 변형 요법(DMT)임을 주목합니다. 이 약물은 MS에서 발견되는 비정상적인 면역 반응에 관여하는 면역 세포의 일종인 CD20 양성 B 세포를 표적으로 함으로써 효과를 발휘합니다. 연간 2회, 단 2시간의 정맥주사로 투여되므로 환자에게 보다 편리하고 효과적인 치료 옵션이 됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Primary progressive multiple sclerosis (PPMS) treatment encompasses medical and therapeutic strategies designed to manage and slow the progression of PPMS-a form of multiple sclerosis marked by a continuous decline in neurological function from the onset, without distinct relapses or remissions. These interventions aim to reduce disease activity, ease symptoms, preserve mobility, and enhance patients' quality of life.

The primary drug categories utilized in the management of primary progressive multiple sclerosis (PPMS) include monoclonal antibodies, immunosuppressants, corticosteroids, and various other drug types. Monoclonal antibodies (mAbs) are synthetically engineered proteins that specifically bind to antigens on affected cells, serving diagnostic or therapeutic functions. These medications are delivered through different routes such as oral, intravenous, and others, and are made available via hospital pharmacies, retail pharmacies, online pharmacies, and additional distribution channels.

The primary progressive multiple sclerosis (PPMS) treatment market size has grown rapidly in recent years. It will grow from $1.02 billion in 2024 to $1.16 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. Growth during the historic period was supported by the increasing incidence of PPMS among older adults, enhanced awareness and knowledge of the condition among patients and medical professionals, higher R&D investments targeting PPMS therapies, greater use of disease-modifying treatments, and amplified governmental support and funding for emerging treatment options.

The primary progressive multiple sclerosis (PPMS) treatment market size is expected to see rapid growth in the next few years. It will grow to $1.92 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. This anticipated growth will be driven by the rising number of clinical trials exploring novel PPMS therapies, progress in diagnostic methods, a growing preference for precision and targeted medicine, improvements in healthcare infrastructure, and stronger collaboration and partnerships between pharmaceutical firms. Key trends expected during the forecast period include innovation in disease-modifying therapies aimed at halting PPMS progression, the application of biomarker studies for personalized treatment, enhanced imaging technologies such as MRI, advancements in neuroprotection and remyelination drug development, and breakthroughs in genetic and molecular patient profiling for more accurate treatment planning.

The growing demand for effective treatments is expected to propel the growth of the primary progressive multiple sclerosis (PPMS) treatment market going forward. Effective treatments are medical interventions that reduce symptoms, improve patient outcomes, or cure a disease or condition. This demand is primarily driven by the rising prevalence of chronic and complex health conditions, which require long-term management and advanced therapeutic interventions to improve patient outcomes and quality of life. These treatments help slow the progression of primary progressive multiple sclerosis (PPMS) by targeting inflammation and preserving neurological function, thereby improving long-term quality of life, reducing disability accumulation, and enhancing patients' ability to manage daily activities with greater independence and stability. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization for gene and cell therapy, the number of gene therapies in Phase III clinical trials reached 33 Phase III gene therapy trials in 2023, an increase of 10% compared to 2022, representing the first quarterly increase since Q3 2022. Therefore, the growing demand for effective treatments drives the growth of the primary progressive multiple sclerosis (PPMS) treatment market.

Major companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are focusing on developing innovative formulations such as monoclonal antibody drugs to enhance the treatment of multiple sclerosis. A monoclonal antibody drug helps in multiple sclerosis by targeting specific immune cells or proteins that cause inflammation and damage to the nervous system, reducing disease activity and slowing the progression of symptoms. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (ocrelizumab), a monoclonal antibody drug, to treat multiple sclerosis (MS) in India. Ocrevus is notable for being the first and only approved disease-modifying therapy (DMT) for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug works by targeting CD20-positive B cells, a type of immune cell involved in the abnormal immune response seen in MS. It is administered as a twice-yearly intravenous infusion for only two hours, offering patients a more convenient and effective treatment option.

In March 2024, Viatris Inc., a US-based healthcare company focused on providing access to medicines, partnered with Mapi Pharma Ltd. to advance the development and commercialization of GA Depot 40 mg for multiple sclerosis treatment. Through this partnership, Viatris supports the regulatory and commercial pathway for GA Depot, a long-acting injectable therapy to improve treatment adherence and address unmet medical needs in managing multiple sclerosis. Mapi Pharma Ltd. is an Israel-based pharmaceutical company specializing in depot technologies and sustained-release formulations for central nervous system disorders, including multiple sclerosis.

Major players in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, Brainstorm Cell Therapeutics Inc.

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary progressive multiple sclerosis (PPMS) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the primary progressive multiple sclerosis (PPMS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary progressive multiple sclerosis (PPMS) treatment market consists of sales of ocrelizumab (ocrevus), mitoxantrone, baclofen, modafinil and oxybutynin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Progressive Multiple Sclerosis (PPMS) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary progressive multiple sclerosis (ppms) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for primary progressive multiple sclerosis (ppms) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary progressive multiple sclerosis (ppms) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Characteristics

3. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Trends And Strategies

4. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Growth Analysis And Strategic Analysis Framework

6. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Segmentation

7. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Regional And Country Analysis

8. Asia-Pacific Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

9. China Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

10. India Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

11. Japan Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

12. Australia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

13. Indonesia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

14. South Korea Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

15. Western Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

16. UK Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

17. Germany Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

18. France Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

19. Italy Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

20. Spain Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

21. Eastern Europe Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

22. Russia Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

23. North America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

24. USA Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

25. Canada Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

26. South America Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

27. Brazil Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

28. Middle East Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

29. Africa Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

30. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Landscape And Company Profiles

31. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Other Major And Innovative Companies

32. Global Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

34. Recent Developments In The Primary Progressive Multiple Sclerosis (PPMS) Treatment Market

35. Primary Progressive Multiple Sclerosis (PPMS) Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기